Phase 0 Clinical Chemoprevention Trial of the AKT Inhibitor SR13668

PURPOSE: SR13668, an orally active AKT pathway inhibitor, has demonstrated cancer chemopreventive potential in preclinical studies. To accelerate the clinical development of this promising agent, we designed and conducted the first-ever phase 0 chemoprevention trial to evaluate and compare the effec...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Reid, Joel M., Walden, Chad, Qin, Rui, Allen Ziegler, Katie L., Haslam, John L., Rajewski, Roger A., Warndahl, Roger, Fitting, Cindy L., Boring, Daniel, Szabo, Eva, Crowell, James, Perloff, Marjorie, Jong, Ling, Mandrekar, Sumithra J., Ames, Matthew M., Limburg, Paul J.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2011
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3061470/
https://ncbi.nlm.nih.gov/pubmed/21372034
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1940-6207.CAPR-10-0313
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak